Boxer Capital Acquires Significant Stake in Corvus Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CRVS?
Source: Fool
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026, valued at approximately $17.55 million, indicating strong confidence in the company.
- Outstanding Stock Performance: As of May 14, 2026, Corvus shares were priced at $13.66, reflecting a 250% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its immuno-oncology therapies.
- Strong Financial Position: Corvus ended the quarter with $236.7 million in cash and marketable securities, expected to fund operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: The ongoing Phase 2 trial is expected to enroll around 200 patients, with preliminary data showing that 75% of patients maintained good responses after treatment cessation, indicating potential in the treatment of atopic dermatitis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVS
Wall Street analysts forecast CRVS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.655
Low
11.00
Averages
13.33
High
16.00
Current: 13.655
Low
11.00
Averages
13.33
High
16.00
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boxer Capital Acquires Significant Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026, valued at approximately $17.55 million, indicating strong confidence in the company.
- Outstanding Stock Performance: As of May 14, 2026, Corvus shares were priced at $13.66, reflecting a 250% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its immuno-oncology therapies.
- Strong Financial Position: Corvus ended the quarter with $236.7 million in cash and marketable securities, expected to fund operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: The ongoing Phase 2 trial is expected to enroll around 200 patients, with preliminary data showing that 75% of patients maintained good responses after treatment cessation, indicating potential in the treatment of atopic dermatitis.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Corvus Pharmaceuticals Shares Drop After Phase 1 Trial Data Release
- Trial Results: Corvus Pharmaceuticals released final data from its Phase 1 trial of soquelitinib for atopic dermatitis, revealing that 50% and 75% of patients achieved a 75% reduction in EASI 75 at a 200 mg dose, yet the results failed to boost market confidence, leading to a ~13% drop in stock price on Thursday.
- Safety Profile: Across all four cohorts analyzed, no significant safety issues were reported, although approximately 42% of patients in both the soquelitinib and placebo groups experienced adverse events, all classified as Grade 1-2, which did not necessitate dose adjustments or discontinuations, indicating a relatively safe profile for the drug.
- Trial Context: The 72-patient trial focused on moderate-to-severe atopic dermatitis patients who had not responded to prior topical or systemic therapies, with soquelitinib designed as an oral therapy to inhibit the immune-modulatory enzyme ITK, showcasing potential efficacy for treatment-resistant patients.
- Future Research: Soquelitinib is currently undergoing the company's SIERRA1 Phase 2 trial, which will evaluate the drug in approximately 200 patients with moderate-to-severe AD, with CEO Richard Miller emphasizing that the Phase 1 data highlights the potential of ITK inhibition to treat a broad range of atopic dermatitis patients, particularly those resistant to other systemic therapies.
See More
Corvus Pharmaceuticals Appoints New Board Member
- New Board Member: Corvus Pharmaceuticals has appointed Dr. Andrew C. Chan to its Board of Directors, bringing 25 years of experience from Genentech where he led the development of several FDA-approved drugs, enhancing the company's expertise in immune modulation and cancer treatment.
- Enhanced Scientific Perspective: Dr. Chan's addition is expected to elevate the scientific perspective of the board, supporting the company's strategy in ITK inhibition and immune modulation, which is anticipated to drive the development of soquelitinib and strengthen market competitiveness in treating immune diseases and cancer.
- Rich Professional Background: Dr. Chan's deep expertise in immunology and his remarkable achievements in academia and industry, particularly in T cell signaling, will provide significant strategic value to Corvus's research and development efforts.
- Clinical Trial Prospects: Soquelitinib, an investigational oral small molecule drug, is currently undergoing a registration Phase 3 clinical trial for relapsed/refractory PTCL, expected to offer a new treatment mechanism for various immune diseases, further solidifying the company's market position.
See More
Corvus Pharmaceuticals Unveils New Drug Data at SID Meeting
- Clinical Trial Progress: Corvus Pharmaceuticals will showcase Phase 1 clinical trial data for soquelitinib at the investor meeting on May 14, 2026, including new immunologic and biomarker data supporting drug-free remissions, which could enhance the company's competitive position in dermatological treatments.
- Key Meeting Arrangement: The meeting will be hosted by CEO Richard A. Miller, M.D., featuring experts from Stanford University discussing the drug's mechanism and its application in atopic dermatitis, likely attracting significant attention from investors and analysts, thereby boosting market confidence.
- Financial Reporting Schedule: The company plans to release its first-quarter 2026 financial results on May 7, 2026, without a conference call, indicating a focus on direct communication with investors, which may influence shareholder expectations regarding the company's future performance.
- New Drug Development Outlook: As a selective ITK inhibitor, soquelitinib is undergoing multiple clinical trials, and if successful, it could open new market opportunities for the company in immunotherapy, particularly in treating relapsed/refractory PTCL and atopic dermatitis.
See More
Corvus' Oral Therapy Potential Underestimated by Analysts
- Significant Clinical Results: Corvus' Soquelitinib demonstrated impressive early trial results for atopic dermatitis, with 75% of patients achieving at least a 75% improvement and 25% experiencing over 90% improvement, indicating its potential as a leading oral therapy in the market.
- Stock Price Surge: Following a bullish analyst call, shares of Corvus Pharmaceuticals (CRVS) jumped nearly 12% on Friday, breaking above their 50-day moving average for the first time since March 13, reflecting increased market confidence in the potential of its oral drug.
- Goldman Sachs Upgrade: Goldman Sachs initiated coverage of Corvus with a 'Buy' rating and a price target of $40, representing a 138% upside from current levels, highlighting the company's competitive edge in the post-Dupixent atopic dermatitis market.
- Investor Sentiment Shift: Retail sentiment for CRVS on Stocktwits shifted from 'bearish' to 'bullish' with high message volumes, as some users anticipate the stock could climb to $100 over the next 12-18 months, indicating optimism about Corvus' future prospects.
See More
Boxer Capital Acquires Significant Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026, valued at approximately $17.55 million, indicating strong confidence in the company.
- Outstanding Stock Performance: As of May 14, 2026, Corvus shares were priced at $13.66, reflecting a 250% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its immuno-oncology therapies.
- Strong Financial Position: Corvus ended the quarter with $236.7 million in cash and marketable securities, expected to fund operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: The ongoing Phase 2 trial is expected to enroll around 200 patients, with preliminary data showing that 75% of patients maintained good responses after treatment cessation, indicating potential in the treatment of atopic dermatitis.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Corvus Pharmaceuticals Shares Drop After Phase 1 Trial Data Release
- Trial Results: Corvus Pharmaceuticals released final data from its Phase 1 trial of soquelitinib for atopic dermatitis, revealing that 50% and 75% of patients achieved a 75% reduction in EASI 75 at a 200 mg dose, yet the results failed to boost market confidence, leading to a ~13% drop in stock price on Thursday.
- Safety Profile: Across all four cohorts analyzed, no significant safety issues were reported, although approximately 42% of patients in both the soquelitinib and placebo groups experienced adverse events, all classified as Grade 1-2, which did not necessitate dose adjustments or discontinuations, indicating a relatively safe profile for the drug.
- Trial Context: The 72-patient trial focused on moderate-to-severe atopic dermatitis patients who had not responded to prior topical or systemic therapies, with soquelitinib designed as an oral therapy to inhibit the immune-modulatory enzyme ITK, showcasing potential efficacy for treatment-resistant patients.
- Future Research: Soquelitinib is currently undergoing the company's SIERRA1 Phase 2 trial, which will evaluate the drug in approximately 200 patients with moderate-to-severe AD, with CEO Richard Miller emphasizing that the Phase 1 data highlights the potential of ITK inhibition to treat a broad range of atopic dermatitis patients, particularly those resistant to other systemic therapies.
See More
Corvus Pharmaceuticals Appoints New Board Member
- New Board Member: Corvus Pharmaceuticals has appointed Dr. Andrew C. Chan to its Board of Directors, bringing 25 years of experience from Genentech where he led the development of several FDA-approved drugs, enhancing the company's expertise in immune modulation and cancer treatment.
- Enhanced Scientific Perspective: Dr. Chan's addition is expected to elevate the scientific perspective of the board, supporting the company's strategy in ITK inhibition and immune modulation, which is anticipated to drive the development of soquelitinib and strengthen market competitiveness in treating immune diseases and cancer.
- Rich Professional Background: Dr. Chan's deep expertise in immunology and his remarkable achievements in academia and industry, particularly in T cell signaling, will provide significant strategic value to Corvus's research and development efforts.
- Clinical Trial Prospects: Soquelitinib, an investigational oral small molecule drug, is currently undergoing a registration Phase 3 clinical trial for relapsed/refractory PTCL, expected to offer a new treatment mechanism for various immune diseases, further solidifying the company's market position.
See More
Corvus Pharmaceuticals Unveils New Drug Data at SID Meeting
- Clinical Trial Progress: Corvus Pharmaceuticals will showcase Phase 1 clinical trial data for soquelitinib at the investor meeting on May 14, 2026, including new immunologic and biomarker data supporting drug-free remissions, which could enhance the company's competitive position in dermatological treatments.
- Key Meeting Arrangement: The meeting will be hosted by CEO Richard A. Miller, M.D., featuring experts from Stanford University discussing the drug's mechanism and its application in atopic dermatitis, likely attracting significant attention from investors and analysts, thereby boosting market confidence.
- Financial Reporting Schedule: The company plans to release its first-quarter 2026 financial results on May 7, 2026, without a conference call, indicating a focus on direct communication with investors, which may influence shareholder expectations regarding the company's future performance.
- New Drug Development Outlook: As a selective ITK inhibitor, soquelitinib is undergoing multiple clinical trials, and if successful, it could open new market opportunities for the company in immunotherapy, particularly in treating relapsed/refractory PTCL and atopic dermatitis.
See More
Corvus' Oral Therapy Potential Underestimated by Analysts
- Significant Clinical Results: Corvus' Soquelitinib demonstrated impressive early trial results for atopic dermatitis, with 75% of patients achieving at least a 75% improvement and 25% experiencing over 90% improvement, indicating its potential as a leading oral therapy in the market.
- Stock Price Surge: Following a bullish analyst call, shares of Corvus Pharmaceuticals (CRVS) jumped nearly 12% on Friday, breaking above their 50-day moving average for the first time since March 13, reflecting increased market confidence in the potential of its oral drug.
- Goldman Sachs Upgrade: Goldman Sachs initiated coverage of Corvus with a 'Buy' rating and a price target of $40, representing a 138% upside from current levels, highlighting the company's competitive edge in the post-Dupixent atopic dermatitis market.
- Investor Sentiment Shift: Retail sentiment for CRVS on Stocktwits shifted from 'bearish' to 'bullish' with high message volumes, as some users anticipate the stock could climb to $100 over the next 12-18 months, indicating optimism about Corvus' future prospects.
See More
